Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation

Pediatric Diabetes

Volumn 13, Issue 8, 2012, Pages 656-660

  Battaglia, Domenica ^a   Lin, Yu Wen ^b   Brogna, Claudia ^a   Crinò, Antonino ^c   Grasso, Valeria ^d   Mozzi, Alessia F ^d   Russo, Lucia ^d   Spera, Sabrina ^c   Colombo, Carlo ^d   Ricci, Stefano ^c   Nichols, Colin G ^b   Mercuri, Eugenio ^a   Barbetti, Fabrizio ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Developmental delay; Glyburide; Infancy onset diabetes; KCNJ11; Mutation

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2;

ARTICLE; BENIGN CHILDHOOD EPILEPSY; CASE REPORT; CHILD; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DNA SEQUENCE; DRUG BLOOD LEVEL; GENE DELETION; GENE MUTATION; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; LEARNING DISORDER; MALE; MOTOR COORDINATION; NEUROLOGICAL COMPLICATION; NEWBORN DIABETES MELLITUS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE;

CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEUROPATHIES; EPILEPSY; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MOTOR SKILLS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PSYCHOMOTOR PERFORMANCE; SEQUENCE DELETION;

EID: 84870051901     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2012.00874.x     Document Type: Article

References (21)

1. Gloyn AL, Pearson ER, Anteliff JF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838-1849.
2. Yorifuji T, Nagashima K, Kurokawa K et al. The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes or later-onset, apparently type 2 diabetes. J Clin Endocrinol Metab 2005: 90: 3174-3178.
3. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005: 54: 2503-2513.
4. Masia R, Koster JC, Tumini S et al. An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of DEND (Developmental Delay, Epilepsy, and Neonatal Diabetes). Diabetes 2007: 56: 328-336.
5. Massa O, Iafusco D, D'Amato E, et al. KCNJ11 mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 2005: 25: 2-27.
6. Russo L, Iafusco D, Brescianini S, et al. Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 2011: 54: 1693-1701.
7. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2008: 93: 1054-1061.
8. Clark RH, McTaggart JS, Webster R, et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science 2010: 329: 458-461.
9. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006: 355: 467-477.
10. Tonini G, Bizzarri C, Bonfanti R, et al. Sulphonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 gene. Diabetologia 2006: 49: 2210-2213.
11. Iafusco D, Bizzarri C, Cadario F, et al. No beta cell desensitisation after a median of 68months on glyburide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia 2011: 54: 2736-2738.
12. Shimomura K, Horster F, de Wet H, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology 2007: 69: 1342-1349.
13. Mlynarski W, Tarasov AI, Gach A, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 2007: 3: 640-645.
14. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006: 49: 2559-2563.
15. Mistri HN, Jangid AG, Shrivastav PS. Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. J Pharm Biomed Anal 2007: 45: 97-106.
16. Wechsler D. Wechsler Intelligence Scale for Children. 3rd edn. San Antonio: Psychological Corporation, 1992.
17. Beery KE. Developmental Test of Visual-Motor Integration. Cleveland: Modern Curriculum Press, 1989.
18. Rubio-Cabezas O, Flanagan SE, Damhuis A, Hattersley AT, Ellard S. K(ATP) channel mutation in infants with permanent diabetes diagnosed after 6months of life. Pediatr Diabetes 2012: XIII.
19. Crai TJ, Shimomura K, Holl RW, Flanagan SE, Ellard S, Ashcroft FM. An in-frame deletion in Kir6.2 (KCNJ11) causing neonatal diabetes reveals a site of interaction between Kir6.2 and SUR1. J Clin Endocrinol Metab 2010: 94: 2551-2557.
20. Caraballo RH, Cersósimo RO, Fejerman N. Childhood occipital epilepsy of Gastaut: a study of 33 patients. Epilepsia 2008: 49: 288-297.
21. Andermann F. Migraine and the benign partial epilepsies of childhood: evidence for an association. Epileptic Disord 2000: 1: S37-S39.